Dexcom Reports Preliminary, Unaudited Results for the Fourth Quarter and Fiscal Year 2025 and Initial 2026 Outlook ...

Some of medtech's most innovative technologies were on display at the Consumer Electronics Show (CES) in Las Vegas this week.

There are exciting advancements in patient standard of care thanks to continuous health monitoring technologies.

Investing.com -- Barclays downgraded DexCom and Insulet, two large-cap diabetes device makers, to Underweight as it expects rising competition in 2026 and 2027 to weigh on valuation multiples and ...

Dexcom (NSDQ:DXCM) today announced preliminary fourth-quarter results that included revenues that topped the consensus ...